BREAKING: Target Test Prep releases Brand New 2026 On Demand GMAT prep course

Redeem

Target Test Prep · GMAT

Choose how you want to prepare

Learn live with an expert or move at your own pace. Every option includes the complete TTP study system.

★★★★★5.0563 reviews
Newsweek Readers’ Choice Awards 2026 winner: Target Test Prep, #1 Test Prep
NEWSWEEK READERS’ CHOICE AWARDS 2026

Target Test Prep was voted #1 Best Test Prep in the 2026 Newsweek Readers’ Choice™ Awards.

GMATLiveTeach Starts Oct 17
Chris Peckover, Target Test Prep GMAT expert
LIVE ONLINE CLASSES

Get Ready for GMAT Test Day Faster with Live Online Classes

with Chris Peckover, 100th-Percentile GMAT Scorer

Oct 17 · Chris Peckover
Sat · 11:00 AM to 2:00 PM ET
Oct 20 · Chris Peckover
Tue, Thu · 8:00 to 10:00 PM ET
Oct 25 · Josh Braslow
Sun · 1:00 to 4:00 PM ET
Included
40 hours of live online classes + 6 months of TTP OnDemand
  • Attend the first class for free
  • Every class is recorded, so you never fall behind
View classes & enroll
Limited seats availableTarget Test Prep
EALiveTeachOnDemand 5 seats left Start anytime
EXECUTIVE ASSESSMENT

Target Test Prep EA OnDemand

Self-paced EA prep. Study on your schedule.

Logan Thompson
EXECUTIVE ASSESSMENT

Sep 6 to Dec 6, 2026

with Logan Thompson

165+ EA score guarantee
$05-day trial no automatic billing
Schedule
Sun · 9:30 AM to 12:30 PM ET
Included
40 hours of live online classes plus six months of access to the complete TTP EA OnDemand course.
  • 165+ EA Score Guarantee
  • 4,100+ Quant, Verbal, and Integrated Reasoning practice questions
  • 400+ hours of in-depth video lessons
  • 3,000+ step-by-step video solutions
View EA class & enroll Start free 5-day trial
Limited cohort · enrollment openTrial includes full course accessTarget Test Prep
GMATOnDemand Start anytime
SELF-PACED MASTERCLASS

Target Test Prep GMAT OnDemand

Complete access from day one. Study on your schedule.

715+ score guarantee
$0to start then $127/mo
  • Personalized study plan and analytics
  • Thousands of lessons and practice questions

Compare the format, schedule, and included access before enrolling. Prices and seat counts shown reflect the supplied offer details.

A certain pharmaceutical firm recently developed a new medic

Expert replies
by rajcools » Sun Apr 29, 2012 7:45 am
A certain pharmaceutical firm recently developed a new medicine, Dendadrine, that provides highly effective treatment of severe stomach disorders that were previously thought to be untreatable. However, to develop the new medicine, the company spent nearly $5 billion in research and development costs. Given the size of the market for Dendadrine and the amount of the initial investment in its development, the company would need to sell Dendadrine at a price that is at least 5 times greater than its variable costs just to break even. Yet the company's management claims that Dendadrine will soon become the major driver of the firm's profits.

Which of the following statements best reconciles the management's claim with the evidence on the expenditures associated with the development of Dendadrine?

a)The pharmaceutical firm expects to be granted patent protection for Dendadrine; drugs under patent protection typically sell at prices that are approximately ten times their variable costs.
b) The development of some pharmaceutical products involves substantial initial expenditures on research, testing, and approval.
c) In clinical tests, Dendadrine has proven far more effective at treating severe stomach disorders than any prior available treatments, without any serious side effects.
d) No competitors are developing or planning to develop new medicines that might compete with Dendadrine in the marketplace.
e) Millions of people suffer from severe stomach disorders, representing an estimated one to two billion dollars every year in revenue.

OA after some discussion
Join the discussion
Source: — Critical Reasoning |

by ice_rush » Sun Apr 29, 2012 12:32 pm
I'd have to go with [spoiler](A)[/spoiler] on this one.

Choices B, C and D can be quickly ruled out - they are mostly out of scope.

Though I did glance at choice (E) for a couple seconds. The fact that millions or even a billion people suffer from stomach disorders does not ensure firm's profitability as it is mentioned in the stem that the firm had already sized up the market.

What's the OA?
Join the discussion

by rajcools » Sun Apr 29, 2012 1:58 pm
OA is A
i was stuck between A and E
and as per OE E is more closer to being a correct answer than u have mentioned.
So waiting for some expert to comment
Join the discussion

by ice_rush » Sun Apr 29, 2012 2:56 pm
not sure if you noticed, but i selected (A)...Is that correct?

don't follow your comment: E is closer to being a correct answer than I have mentioned??
Join the discussion

by rajcools » Sun Apr 29, 2012 8:52 pm
yeah OA is A

sorry for convoluted language I meant we need some strong reason to eliminate E
Join the discussion

by agarwalmanoj2000 » Sun Apr 29, 2012 11:12 pm
I am also stuck between A and E.

rajcools: Can you share the OE?
Join the discussion

by shantanu86 » Sun Apr 29, 2012 11:31 pm
Hi rajcools, agarwalmanoj2000;

IMO it definitely [spoiler][A][/spoiler]
Here is the comparison-

Argument-
The drug will have major contribution to profits despite the fact that company must sell it for > 5X price.
e) Millions of people suffer from severe stomach disorders, representing an estimated one to two billion dollars every year in revenue
- This option only indicates that there is a big market for the drug but since competitors don't have to invest in R&D they can effectively sell it for much less price for same profit (2x or so) effectively eating into market share of the firm and causing losses to it.
a)The pharmaceutical firm expects to be granted patent protection for Dendadrine; drugs under patent protection typically sell at prices that are approximately ten times their variable costs.
- This option clearly indicates that the drug is protected by patent and hence competition can't sell it without paying out loyalty.. effectively the patent protects first X5 margins. Further the option indicates that such patent protected drugs typically sell 10X the price.

Hope it helps!!
If you feel like it, hit thanks :)
Join the discussion

by rajcools » Mon Apr 30, 2012 7:41 am
Here is the OE

The argument provides information about the substantial costs associated with the development of Dendadrine. Yet the management views Dendadrine as a highly profitable project. In order to reconcile these claims, we need to demonstrate that the drug will be able to generate profits that will more than compensate for the high initial expenditures associated with its development.

(A) CORRECT. If management expects to earn patent protection for the new drug, then the company can also expect to charge the unusually high prices that will more than compensate for the initial research and development costs. Note that the patent protection is likely to result in prices twice as high as those necessary for the company to recoup its costs, thus leading to substantial profits.

(E) Though this supports the idea that the market for Dendadrine is very large and will generate revenues in excess of $5 billion within a few years, it does not specifically support the contention that the drug will be profitable in the face of the unusually high costs associated with it
Join the discussion